Rocket Lab is Still in the Red. Here Are 4 Reasons to Buy the Stock Anyway.

Rocket Lab has nearly quadrupled over the past 12 months and is expected to grow revenue from $602 million in 2025 to $1.59 billion in 2028, with profitability projected by 2028. The company launched 21 Electron rockets in 2025, has already launched seven more year-to-date, and is targeting more than 20 launches for the full year while advancing its Neutron rocket and broader space-services strategy. A key catalyst is its $816 million SDA contract to design and manufacture 18 satellites, plus the recent acquisition of Mynaric to expand communications capabilities.

Analysis

The market is treating this as a pure launch-growth story, but the more important second-order effect is that Rocket Lab is moving from a cyclical launch vendor to a defense-adjacent systems supplier with higher contractual visibility. That mix should compress revenue volatility over time and improve the quality of backlog, but it also raises execution risk because the business is becoming more capital-intensive just as it scales into larger government programs. The real inflection is not Electron cadence; it is whether the company can convert program wins into repeatable multi-year procurement relationships before competitors or primes bundle them out.

The bullish setup on SDA exposure is partly a policy trade, not just a technology trade. Missile-defense and space-network budgets are less sensitive to near-term commercial launch pricing, so the stock’s multiple can stay elevated as long as appropriations remain intact; however, that also makes the name vulnerable to Washington timing risk if budget authority slips or contract awards get delayed by quarters. In other words, the next leg is likely driven by contract conversion and margin proof, not by launch-count headlines.

Consensus appears to be underestimating two things: dilution of upside from financing needs, and the possibility that the current valuation already discounts a lot of the Neutron optionality. If Neutron slips, investors will likely re-rate the stock on the basis of the existing business, where the path to profitability is still a multi-quarter story. The more interesting asymmetry is that execution beats could justify a premium for years, but any hiccup in satellite manufacturing or integration would hit both growth and margin narratives at once.

Key Decisions for Investors

• Stay long RKLB only on pullbacks into earnings or launch cadence weakness; use a 3-6 month horizon and size for high volatility because the multiple embeds execution perfection.
• Pair trade: long RKLB / short BKSY for the next 1-2 quarters if you want exposure to defense-space budget growth with cleaner platform optionality; BKSY has less operating leverage to the same procurement theme.
• Buy RKLB upside via call spreads rather than outright stock for a 6-9 month horizon; the trade works if Neutron progress and SDA monetization keep momentum, while limiting downside if delivery slips.
• If you are already long, hedge event risk around contract updates and launch milestones with short-dated puts; the stock is likely to gap on timing misses even if the medium-term thesis remains intact.
• Avoid chasing at current valuation unless you believe the company can scale into a sustained systems franchise; otherwise the risk/reward is asymmetric to the downside if revenue re-acceleration stalls for even two quarters.